Novartis has agreed to pay $2 billion upfront to acquire a next-generation PI3Kα inhibitor for breast cancer from Synnovation. The Swiss pharmaceutical company is seeking a more selective version of this drug class despite already marketing Piqray, which targets the same pathway.
The acquisition reflects the pharmaceutical industry's push toward next-generation versions of existing drug classes. Companies are investing heavily in more selective and potentially safer versions of proven therapeutic targets, even when they already have approved drugs in the same category.